Get started
Author

Tomohiro Ozaki

Observed names: T. Ozaki, TOMOHIRO OZAKI, 尾崎, 知博
ORCID: 0000-0002-8178-4171
Observed ORCID: 0000-0002-8178-4171
OpenAlex ID: A5065856332
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · Kazuhiko Nakagawa, Edward B Garon, et al. · The Lancet Oncology · 628
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
2020 · Isamu Okamoto, Hiroshi Nokihara, et al. · JAMA Oncology · 71
Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
2020 · Ryoji Kato, Hidetoshi Hayashi, et al. · Journal for ImmunoTherapy of Cancer · 65
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
2025 · Kentaro Tanaka, Jun Sugisaka, et al. · Nature Communications · 28
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
2007 · Toshio Shimizu, Taroh Satoh, et al. · International Journal of Clinical Oncology · 26
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer
2021 · Shinichiro Suzuki, Koji Haratani, et al. · European Journal of Cancer · 23
PDF
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors
2009 · Toshio Shimizu, Isamu Okamoto, et al. · Cancer Chemotherapy and Pharmacology · 22
Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer
2020 · TAKASHI KUROSAKI, HISATO KAWAKAMI, et al. · In Vivo · 21
PDF
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer
2009 · Kenji Tamura, Isamu Okamoto, et al. · European Journal of Cancer · 18
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
2022 · Yasushi Goto, Atsuhisa Tamura, et al. · JTO Clinical and Research Reports · 14
PDF
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
2014 · Kimio Yonesaka, Tomohiro Suzumura, et al. · PubMed · 14
Tumor Cyclooxygenase-2 Gene Suppresses Local Immune Responses in Patients with Hepatocellular Carcinoma
2006 · Akemi Iwamoto, Masahide Ikeguchi, et al. · Tumori Journal · 12
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L
2023 · Takehiro Uemura, Hirotsugu Kenmotsu, et al. · Cancer Medicine · 9
PDF
Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).
2019 · Isamu Okamoto, Hiroshi Nokihara, et al. · Journal of Clinical Oncology · 8
The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease
2022 · Yusuke Kawanaka, Yuto Yasuda, et al. · Respiratory Investigation · 6
PDF
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer
2020 · Hidetoshi Hayashi, Masakazu Ogura, et al. · The Oncologist · 5
PDF
Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report
2022 · Kana Fujimoto, Satomi Watanabe, et al. · Thoracic Cancer · 4
P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan
2022 · Takashi Kijima, Koichi Azuma, et al. · Annals of Oncology · 3
Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG030404.
2011 · K. Tanaka, J. Mizusawa, et al. · Journal of Clinical Oncology · 2
Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study
2007 · Kazuhiko Nakagawa, Tomohiro Ozaki, et al. · Haigan · 2
PDF
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
2007 · Tomohiro Ozaki, Kenji Tamura, et al. · PubMed · 1
Tolerability and effectiveness of definitive chemoradiotherapy in locally advanced lung cancer patients with combined pulmonary fibrosis and emphysema
2026 · Kana Fujimoto, Mariko Kogo, et al. · Cancer Treatment and Research Communications
SY09-3 The role of fluoropyrimidines in HER2-negative early breast cancer
2023 · Satomi Watanabe, Tomohiro Ozaki, et al. · Annals of Oncology
PDF
Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
2023 · Koji Haratani, Atsushi Nakamura, et al. · Cancer Research
MA03.11 Chemotherapy After PD-1 Inhibitors Versus Chemotherapy Alone in Patients with Non–Small Cell Lung Cancer (WJOG10217L)
2019 · E. Miyawaki, R. Kato, et al. · Journal of Thoracic Oncology
PDF
Works count: 31
Citation count: 982
H-index: 12
I10-index: 12
Year
Topic
Type